logo-loader
viewShield Therapeutics PLC

Shield Therapeutics encouraged by US interest in iron deficiency treatment

Snapshot

  • Developed a breakthrough iron deficiency drug 

  • Feraccru, known as Accrufer in the States, recently won approval in the US

  • Treatment awarded a broad label to treat iron deficiency in adults, significantly widening its potential audience 

  • Shield has tied up an exclusive deal in China with ASK Pharm

 

Shield Therapeutics PLC -

Quick facts: Shield Therapeutics PLC

Price: 121 GBX

LSE:STX
Market: LSE
Market Cap: £141.8 m
Follow

Evidence from clinical studies shows it provides long-term treatment for maintaining the body’s iron stores. In our view, these factors provide a solid support for negotiating attractive deal terms. 

Emma Ulker, Proactive Research

What Shield does

Shield Therapeutics PLC (LON:STX) is a specialty pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals.

Its lead asset, Feraccru (Accrufer in the States), is an oral treatment for iron deficiency with or without anaemia, which is approved in Europe and the US.

The US opportunity alone could be worth in excess of US$1bn, analysts reckon.

A deal with ASK Pharm (Beijing Aosaikang Pharmaceutical), covers China, Hong Kong, Macau and Taiwan to market Ferracru.

 

About Feraccru

The drug has a range of features that help differentiate it from the more established iron treatments including:

• Twice-daily dosing without food providing high iron availability

• Raises haemoglobin and iron levels effectively

• Prolonged therapy maintains Hb levels

• Well tolerated

• Non-inferior to IV iron

 

How it is doing

In August, a reanalysis of the AEGIS-H2H study comparing oral Feraccru /Accrufer against intravenous iron therapy confirms Shield's product is a credible alternative to IV therapy for iron deficiency anaemia, and, corrects anaemia and maintains iron levels over the long term.

In July it announced it would take kidney disease treatment forward to phase III study, potentially starting in 2022 subject to finance being available. Hyperphosphatemia is a condition where due to renal failure there is too much phosphorus present in the blood.

Shield said that the study demonstrated that PT20 treatment for 28 days resulted in a statistically significant and dose-dependent reduction in serum phosphate concentration and was generally well tolerated.

 

What the boss says: Tim Watts, chief executive 

"We are very pleased that the reanalysis of the AEGIS-H2H study data demonstrates that Feraccru/Accrufer is a credible alternative to IV therapy and offers economic advantages."

“Having resolved the anomalies seen in the original analysis the study results can now be used with confidence for further health economics analysis and to support pricing and reimbursement applications in Europe."


 

Video

 

What the broker says

House broker Peel Hunt said in August the new findings on its Feraccru /Accrufer will be beneficial to sign up of a partner for the US market, while they are also supportive of the existing EU and Chinese commercial partners’ marketing efforts.

“Feraccru’s comparable improvement in haemoglobin in the long-term data against IV, combined with its greater tolerability, significantly more convenient oral administration, and compelling economic benefits, constitutes a very strong marketing package for EU commercialisation partner Norgine to leverage into the market.”

 “We believe this will have positive implications for health economic outcomes, pricing strategies and partnering opportunities,” analysts at Edison Group added.

“The next key inflection point is a US partnering deal; we expect Accrufer launch later this year once a partner has been found.”

 

 

What the analyst says 

"The outcomes of the analysis are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. This includes supporting STX’s partner Norgine to negotiate on pricing and coverage decisions in the broader European markets as well for ASK Pharm, the company’s partner in China," said Proactive's analyst Emma Ulker.

"A licensing deal in the US for Accrufer can start to unlock the world’s largest iron replacement market which represents c70% of the estimated US$3bn value of the global market."

SEE FULL REPORT HERE

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive...

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis...

2 days, 14 hours ago

3 min read